IRCT20210519051345N1 IRCT 2021-06-14 Tabriz University of Medical Sciences In vivo Bioequivalence study of Ticagrelor Tablet In vivo Bioequivalence study of Ticagrelor 90 mg Tablet manufactured by Sobhan Daroo Co. on 24 volunteers compared with reference product 2021-08-21 anticipated 24 Complete https://irct.ir/trial/56485 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other, Randomization description: Using the Table of Random Numbers, Blinding description: In this study, Volunteers participating will be blinded to the type of product they are taking in each period (test or reference product). This means that the product will be given to the volunteers for administration outside the original packaging. Bioequivalence In the present study, no diseases will be examined and products will be administered by healthy volunteers.. Intervention group: Healthy volunteers. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There are no more informaton.